Company newsCompany release

Johnson & Johnson JNJ

Johnson & Johnson presents early Phase 1 data on prostate cancer combination

No Grade 3 or higher treatment-related adverse events were reported at the recommended regimen in the Phase 1 study of pasritamig and JNJ-9401, now in Phase 3 development.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Johnson & Johnson said on November 8, 2026, that early Phase 1 results for its investigational combination of pasritamig and JNJ-9401 showed prostate-specific antigen (PSA) reductions in advanced prostate cancer.

At the recommended regimen, 11 of 15 patients had PSA reductions of at least 50%, and 7 of 15 had reductions of at least 90%. The company said the findings are preliminary and based on a small number of patients.

Key facts

Recommended regimen
JNJ-9401 200 mg subcutaneously plus pasritamig 300 mg intravenously, every six weeks
Patients with PSA reductions of at least 50%
11 of 15
Presentation
Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, late-breaking oral session

All JNJ news

Source: The company's release on PR Newswire, November 8, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

Johnson & Johnson first, then the newest

All company news